Hereditary breast-ovarian cancer: Clinical findings and medical management

Plastic Surgical Nursing

Volumn 27, Issue 3, 2007, Pages 124-127

  Marshall, Megan ^a,b   Solomon, Sheila ^a  

^a ALLEGHENY GENERAL HOSPITAL   (United States)

^b Allegheny Cancer Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANAMNESIS; BREAST TUMOR; FAMILIAL CANCER; FEMALE; GENETIC COUNSELING; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETICS; HUMAN; INFORMED CONSENT; MASTECTOMY; MUTATION; ORGANIZATION AND MANAGEMENT; OVARIECTOMY; OVARY TUMOR; PATIENT EDUCATION; PEDIGREE; PRACTICE GUIDELINE; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SENSITIVITY AND SPECIFICITY; SYNDROME; TUMOR SUPPRESSOR GENE;

BREAST NEOPLASMS; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC COUNSELING; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; HUMANS; INFORMED CONSENT; MASTECTOMY; MEDICAL HISTORY TAKING; MUTATION; NEOPLASTIC SYNDROMES, HEREDITARY; OVARIAN NEOPLASMS; OVARIECTOMY; PATIENT EDUCATION; PEDIGREE; PRACTICE GUIDELINES; RISK ASSESSMENT; RISK REDUCTION BEHAVIOR; SENSITIVITY AND SPECIFICITY; SYNDROME;

EID: 34848888382     PISSN: 07415206     EISSN: 15501841     Source Type: Journal    
DOI: 10.1097/01.PSN.0000290280.48197.e7     Document Type: Review

References (21)

1. American Cancer Society. (2007). Cancer facts and figures 2007 [Electronic version]. American Cancer Society, Inc. Retrieved May 29, 2007, from http://www.cancer.org
2. American Society of Clinical Oncology. (1996).American Society of Clinical Oncology policy statement: Genetic testing for cancer susceptibility, adopted on February 20, 1996. Journal of Clinical Oncology, 14, 1730-1736.
3. American Society of Clinical Oncology. (2003). American Society of Clinical Oncology policy statement update: Genetic testing for cancer susceptibility. Journal of Clinical Oncology, 21, 2397-2406.
4. Daly, M. B., Axilbund, J. E., Bryant, E., Buys, S., Eng, C., Farrell, C. D., et al. (2007). NCCN Clinical Practice Guidelines in Oncology: Genetic/familial high-risk assessment: Breast and ovarian [Electronic version]. National Comprehensive Cancer Network. Retrieved May 29, 2007, from http://www.nccn.org/default.asp
5. Domchek, S. M., Eisen, A., Calzone, K., Stopfer, J., Blackwood, A., & Weber B. L. (2003). Application of breast cancer risk prediction models in clinical practice. Journal of Clinical Oncology, 21(4), 593-601.
6. Evans, M. (2001). Identifying and managing hereditary risk for breast and ovarian cancer. A continuing medical education medical genetics series (pp. 1-22). Chicago, IL: American Medical Association.
7. Fisher, B., Costantino, J. P., Wickerham, D. L., Redmond, C. K., Kavanah, M., Cronin, W. M., et al. (1998). Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. Journal of the National Cancer Institute, 90(18), 1371-1388.
8. Ford, D., Easton, D. F., Stratton, M., Narod, S., Goldgar, D., Devilee, P., et al. (1998). Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. American Journal of Human Genetics, 62, 676-689.
9. Geller, G., Botkin, J. R., Green, M. J., Press, N., Biesecker, B. B., Wilfond, B., et al. (1997). Genetic testing for susceptibility to adult-onset cancer. The process and content of informed consent. The Journal of the American Medical Association, 277, 1467-1474.
10. Hall, J. M., Lee, M. K., Newman, B., Morrow, J. E., Anderson L. A., Huey, B., et al. (1990). Linkage of early-onset familial breast cancer to chromosome 17q21. Science, 250, 1684-1689.
11. Kauff, N. D., Satagopan, J. M., Robson, M. E., Scheuer, L., Hensley, M., et al. (2002). Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. New England Journal of Medicine, 346, 1609-1615.
12. Lakhani, S. R. (1999). The pathology of hereditary breast cancer. Disease Markers, 15, 113-114.
13. Lindor, N. M., Green, M. H., & the Mayo Familial Cancer Program. (1998). Special article: The concise handbook of family cancer syndromes. Journal of the National Cancer Institute, 90(14), 1039-1052.
14. McKinnon, W. C., Baty, B. J., Bennett, R. L., Magee, M., Neufeld-Kaiser, W. A., Peters, K. F., et al. (1997). Predisposition genetic testing for late-onset disorders in adults. A position paper of the National Society of Genetic Counselors The Journal of the American Medical Association, 278, 1217-1220.
15. Mulvihill, J., Safyer, A. W., & Bening, J. K. (1982). Prevention in familial breast cancer: Counselling and prophylactic mastectomy. Preventive Medicine, 11, 500-511.
16. National Society of Genetic Counselors. (2005). Genetic counseling as a profession. Retrieved May 29, 2007, from http://www.nsgc.org
17. Rebbeck, T. R., Lynch, H. T., Neuhausen, S. L., Narod, S. A., Van't, V. L., Garber, G. E., et al. (2002). Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. New England Journal of Medicine, 346, 1616-1622.
18. Saslow, D., Boetes, C., Burke, W., Harms, S., Leach, M. O., Lehman, C. D., et al. (2007). American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA: A Cancer Journal for Clinicians, 57(2), 75-89.
19. Schneider, K. A. (2002). Hereditary cancer syndromes. In Counseling about cancer: Strategies for genetic engineering (2nd ed., pp. 82-84). New York: Wiley-Liss.
20. Thull, D. L., & Vogel, V. G. (2004). Recognition and management of hereditary breast cancer syndromes. The Oncologist, 9, 13-24.
21. Wooster, R., Neuhausen, S. L., Mangion, J., Quirk, Y., Ford, D., Collins, N., et al. (1994). Localization of a breast cancer susceptibility gene (BRCA2) to chromosome 13q12-13. Science, 265, 2088-2090.